In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid

Drug Metabolism and Disposition

Volumn 35, Issue 7, 2007, Pages 1157-1164

  Gorman, Gregory S ^a   Coward, Lori ^a   Kerstner Wood, Corenna ^a   Cork, Lea ^a   Kapetanovic, Izet M ^b   Brouillette, Wayne J ^c   Muccio, Donald D ^c  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9CUAB30; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; ENZYME; GLUCURONIDE; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A9; ISOENZYME; RETINOID X RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOTRANSFORMATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONJUGATE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DRUG METABOLISM; ENZYME MECHANISM; FEMALE; GENDER; GLUCURONIDATION; HUMAN; HUMAN CELL; IN VITRO STUDY; KINETICS; LIVER MICROSOME; MALE; METABOLITE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; RAT; SPECIES;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; DRUG STABILITY; FATTY ACIDS, UNSATURATED; FEMALE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; KINETICS; MALE; METABOLIC DETOXICATION, PHASE I; METABOLIC DETOXICATION, PHASE II; MICROSOMES, LIVER; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; NAPHTHALENES; OXIDATION-REDUCTION; OXIDOREDUCTASES, N-DEMETHYLATING; RATS; RECOMBINANT PROTEINS; RETINOID X RECEPTORS; RETINOIDS; SEX FACTORS; SPECIES SPECIFICITY;

CANIS FAMILIARIS; RATTUS;

EID: 34250700017     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.013938     Document Type: Article

References (30)

1. Abu-Abed SS, Beckett BR, Chiba H, Chithalen JV, Jones G, Metzger D, Chambon P, and Petkovich M (1998) Mouse P450RAI (CYP26) expression and retinoic acid-inducible retinoic acid metabolism in F9 cells are regulated by retinoic acid receptor γ and retinoid X receptor α. J Biol Chem 273:2409-2415.
2. Aoyama TY, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, and Gelboin HV (1989) Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem 264:10388-10395.
3. Cai Y, Dai T, Ao Y, Konishi T, Chuang KH, Lue Y, Chang C, and Wan YY (2003) Cytochrome P450 genes are differently expressed in female and male hepatocytes retinoid X receptor α-deficient mice. Endocrinology 144:2311-2318.
4. Chen H and Juchau MR (1998) Biotransformation of 13-cis- and 9-cis-retinoic acid to all-trans-retinoic acid in rat conceptal homogenates. Evidence for catalysis by a conceptal isomerase. Drug Metab Dispos 26:222-228.
5. Chithalen JV, Luu L, Petkovich M, and Jones G (2002) HPLC-MS/MS analysis of the products generated from all-trans-retinoic acid using recombinant human CYP26A. J Lipid Res 43:1133-1142.
6. Crouch GD and Helman LJ (1991) All-trans-retinoic acid inhibits the growth of human rhabdomyosarcoma cell lines. Cancer Res 51:4882-4887.
7. Delia D, Aiello A, Lombardi L, Pelicci PG, Grignani F, Grignani F, Formelli F, Menard S, Costa A, Veronesi U, et al. (1993) N-(4-hydroxyphenyl) retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 53:6036-6041.
8. Ebner T and Burchell B (1993) Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family. Drug Metab Dispos 21:50-55.
9. Green MD, King CD, Mojarrabi B, Mackenzie PI, and Tephly TR (1998) Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos 26:507-512.
10. Grubbs CJ, Hill DL, Bland KI, Beenken SW, Lin TH, Eto I, Atigadda VR, Vines KK, Brouillette WJ, and Muccio DD (2003) 9cUAB30, an RXR specific retinoid, and/or tamoxifen in the prevention of methylnitrosourea-induced mammary cancers. Cancer Lett 201:17-24.
11. Han IS and Choi JH (1996) Highly specific cytochrome P450-like enzymes for all-trans-retinoic acid inT47D human breast cancer cells. J Clin Endocrinol Metab 81:2069-2075.
12. 6-testosterone from testosterone. Drug Metab Dispos 18:974-979.
13. Lin JH and Lu AY (1997) Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 49:403-449.
14. Loudig O, Maclean GA, Dore DL, Luu L, and Petkovich M (2005) Transcriptional co-operativity between distant retinoic acid response elements in regulation of Cyp26A1 inducibility. Biochem J 392:241-248.
15. McSorley LC and Daly AK (2000) Identification of human cytochrome P450 isoforms that contribute to A11-trans-retinoic acid 4-hydroxylation. Biochem Pharmacol 60:517-526.
16. Nadin L and Murray M (1999) Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes. Biochem Pharmacol 58:1201-1208.
17. Nagata K, Liberato DJ, Gillette JR, and Sasame HA (1986) An unusual metabolite of testosterone. Drug Metab Dispos 14:559-565.
18. Parkinson A (1996) Toxicology: The Basic Science of Poisons, 5th ed, chapter 6 (Klassen CD ed) McGraw-Hill, New York.
19. Pelkonen O, Turpeinen M, Uusitalo J, Rautio A, and Raunia H (2005) Prediction of drug metabolism and interactions on the basis of in vitro investigation. Basic Clin Pharmacol Toxicol 96:167-175.
20. Rettie AE, Sheffels PR, Korzekwa KR, Gonzalez FJ, Philpot RM, and Baillie TA (1995) CYP4 isozyme specificity and the relationship between ω-hydroxylation and terminal desaturation of valproic acid. Biochemistry 34:7889-7895.
21. Rubin M, Fenig E, Rosenauer A, Menendez-Botet C, Achkar C, Bentel JM, Yahalom J, Mendelsohn J, and Miller WH Jr (1994) 9-Cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein. Cancer Res 54:6549-6556.
22. Sakaguchi K, Green M, Stock N, Reger TS, Zunic J, and King C (2004) Glucuronidation of carboxylic acid containing compounds by UDP- glucuronosyltransferase isoforms. Arch Biochem Biophys 424:219-225.
23. Shapiro BH, Agrawal AK, and Pampori NA (1995) Gender differences in drug metabolism regulated by growth hormone. Int J Biochem Cell Biol 27:9-20.
24. Shimada T, Yamazaki H, Minura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
25. Shirley MA, Bennani YL, Boehm MF, Breau AP, Pathirnan C, and Ulm EH (1996) Oxidative and reductive metabolism of 9-cis-retinoic acid in the rat. Drug Metab Dispos 24:293-302.
26. Shirley MA, Wheelan P, Howell SR, and Murphy RC (1997) Oxidative metabolism of a rexinoid and rapid phase II metabolite identification by mass spectrometry. Drug Metab Dispos 25:1144-1149.
27. Sonneveld E, van den Brink CE, van der Leede BM, Schulkes RK, Petkovinch M, van der Burg B, and van der Saag PT (1998) Human retinoic acid (RA) 4-hydroxylase (CYP26) is highly specific for all-trans-RA and can be induced through RA receptors in human breast and colon carcinoma cells. Cell Growth Diff 9:629-637.
28. Sun SY, Yue P, Dawson MI, Shroot B, Michel S, Lamph WW, Heyman RA, Teng M, Chandraratna RAS, Shudo K, et al. (1997) Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res 57:4931-4939.
29. Thummel KE and Wilkinson GR (1998) In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430.
30. Wu Q, Dawson MI, Zheng Y, Hobbs PD, Agadir A, Jong L, Li Y, Liu R, Lin B, and Zhang XK (1997) Inhibition of trans-retinoic acid-resistant human breast cancer cell growth by retinoid X receptor-selective retinoids. Mol Cell Biol 17:6598-6608.